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INTRODUCTION
In recent years, the rate of infection caused by the opportunistic human fungal pathogen Candida glabrata has increased significantly. The latest data show that the proportion of candidemia caused by C. glabrata ranges from about 11.2% in Brazil to 29% in North American (Arendrup et al. 2013; Vale-Silva et al. 2013; Arendrup 2014) . Infection by C. glabrata is also predominantly associated with intensive care unit patients. Almost 30% of candidemia cases in intensive care units are caused by C. glabrata, with a mortality rate of 58% (Ruan et al. 2008) . While the primary cause of candidiasis is C. albicans, C. glabrata is now the second most common pathogen that causes candidiasis. Notably, studies have shown a recent increasing trend of C. glabrata infections is tightly associated with increased resistance to antifungal drugs. For example, the rate of resistance to fluconazole was 9% in the USA between 1992 and 2001, but increased to 14% in the period between 2001 and 2010 (Pfaller et al. 2012) . Moreover, a comprehensive study in Denmark suggested that high rates of azole resistance in C. glabrata also exist in Europe (Arendrup et al. 2013) . Therefore, drug resistance in C. glabrata has been becoming an emerging clinical problem and a major threat to human health.
Unlike bacterial infection, there are limited types of antifungal drugs that effectively treat candidiasis. Because antifungals of the azole class exhibit advantages such as a low rate of side effects, low toxicity and a high therapeutic index, it has been employed as the first-line therapy to treat candidiasis for years (Nabili et al. 2016) . However, C. glabrata is intrinsically less sensitive to azoles and can rapidly develop drug resistance upon exposure (Vale-Silva and Sanglard 2015) . Molecular analyses by assaying the vast majority of azole-resistant C. glabrata clinical isolates have identified upregulation of multiple essential multidrug efflux genes, e.g. the ATP-binding cassette transporter genes CDR1, CDR2,and SNQ2 as the main cause of azole resistance (Vermitsky and Edlind 2004; Sanguinetti et al. 2005; Torelli et al. 2008) . In particular, upregulation of these genes was shown to be controlled by Pdr1, a zinc finger transcription factor that has been recognized as a master regulator of drug resistance in C. glabrata (Tsai et al. 2006 (Tsai et al. , 2010 Paul, Schmidt and Moye-Rowley 2011) . To date, studies on Pdr1-mediated regulation in drug resistance have mainly focused on characterization of Pdr1 downstream targets and genomic mutations. For example, it has been documented that gain-of-function mutations, which were distributed throughout the entire sequence of PDR1, were required for hyperactivation of Pdr1 and accordingly overexpression of the ABC transporter genes in azole-resistant clinical isolates (Vermitsky et al. 2006; Ferrari et al. 2009; Caudle et al. 2011) .
While much is known about the role of Pdr1 in regulating the expression of genes required for drug resistance, study of how Pdr1 itself is regulated is still in its infancy (Paul, Schmidt and Moye-Rowley 2011, Paul, Bair and Moye-Rowley 2014) . In Saccharomyces cerevisiae, the C. glabrata Pdr1 homolog ScPdr3 was found to autoregulate its own transcription by binding to the pleiotropic drug response element (PDRE) sites of the promoter (Delahodde, Delaveau and Jacq 1995) . Consistently, a recent study in C. glabrata has shown that Pdr1 appears to regulate its own expression using a similar strategy, and more importantly, the mediator complex subunit Gal11A physically interacts with the C-terminal activation domain of Pdr1 through its KIX domain and actively participates in Pdr1 activation, as this interaction facilitates the recruitment of transcriptional machinery for gene activation of Pdr1 targets (Thakur et al. 2008; Paul, Schmidt and Moye-Rowley 2011; Nishikawa et al. 2016) .
To obtain more details about the role of Pdr1 in regulating C. glabrata drug resistance, we utilized epitope-tagged versions of Pdr1 in which three copies of the FLAG epitope were fused inframe at either the N-or C-terminus. To our surprise, we found that a C-terminal modification on Pdr1 results in abrogation of azole resistance in a matched pair of C. glabrata azole-resistant (Wild6) and azole-susceptible (Wild5) clinical isolates. The Cterminal modification of Pdr1 leads to reducing levels of this fusion protein; however, this cannot be fully explained by activation of an ubiquitin-proteasome proteolytic pathway. Instead, we provide a list of genetic and biochemical evidence showing that the C-terminal modification significantly decreased the binding of Pdr1 to the PDREs in its own promoter, promoted an irregular mislocalization of Pdr1 to cytoplasm and thereby disrupted the transcriptional autoregulation of this master regulator. Taken together, our data reveal a crucial role of the C-terminal sequence of Pdr1 in its stability and functionality, which may be used as a novel therapeutic strategy for treating azole-resistant C. glabrata.
MATERIALS AND METHODS

Microorganisms and media
The C. glabrata strains used in this study are listed in Table S1 (Supporting Information). Four matched pairs of C. glabrata clinical isolates were included (Wild1 and Wild2, Wild3 and Wild4, Wild5 and Wild6, Wild7 and Wild8). YPD rich medium (2% peptone, 2% D-glucose, 1% yeast extract), synthetic medium containing 2% glucose without uracil (SD-URA), YNB (0.67% yeast nitrogen base, 2% D-glucose) agar plates containing 0.1% 5-fluoroorotic acid (5-FOA) and YPD plates containing 100 μg/ml nourseothricin (nat) (clonNAT, Werner BioAgents) (YPD-NAT) were prepared as described previously (Yáñez-Carrillo et al. 2015) . Escherichia coli strain DH5a, cultured in Luria-Bertani (LB) medium, was used for the plasmid DNA preparation. All of the plasmids used in this study are listed in Table S2 (Supporting  Information) .
Gene deletion strategy
The wild-type C. glabrata strains used here were a pair of clinical isolates, Wild5 and Wild6. As the dominant-selectable gene NAT1 has to be recycled, we adapted a gene deletion strategy (Yáñez-Carrillo et al. 2015) , as shown in Fig. S1 (Supporting Information). All of the primers used in this study are shown in Table S3 (Supporting Information) . Briefly, to construct gene deletion cassettes, we used fusion PCR to fuse ∼500-bp homologous flanking regions (5 and 3 homologous regions) of the target gene to the NAT marker ( Supporting Information, Fig. S1A ). The NAT marker contains the NAT1 gene driven by the TEF1 promoter with two copies of 34-bp FRT on both sides of it, subcloned from pYC44 (Yáñez-Carrillo et al. 2015) . Deletion cassettes were transformed into yeast cells using a lithium acetate protocol, as previously described (Supporting Information, Fig. S5B ) (Yáñez-Carrillo et al. 2015) . Correct genomic integration was confirmed by PCR ( Supporting Information, Fig. S1B ). To recycle the NAT marker, plasmid pRD16 was transformed into the yeast cell to flip away the NAT marker ( Supporting Information, Fig. S1C ). As pRD16 contains the URA3 gene, yeast cells transformed with pRD16 are URA3-defective. We first knocked out the URA3 gene in the Wild5 and Wild6 backgrounds, generating TYS and TYR.
Other genes of interest, as well as the PDRE sequence in the PDR1 promoter, were disrupted in the same way.
Epitope tagging strategy
Based on a C-terminal tagging method described previously, we developed the N-terminal tagging strategy (Supporting Information, Fig. S2 ). Plasmids pYC46 and pYC48 were used to tag 3 × FLAG or 3 × Hemagglutinin (HA) at the N-or C-terminal of the target gene in its native locus, which were generously provided by Irene Castaño (Yáñez-Carrillo et al. 2015) . According to the protocol described previously (Yáñez-Carrillo et al. 2015) , we tagged Pdr1 at C-terminal with 3 × FLAG and Gal11A at Cterminal with 3 × HA.
To introduce a 3 × FLAG into the N-terminal of Pdr1, ∼500 bp of the 5 -UTR, Pdr1 Up, was amplified from C. glabrata genomic DNA with #Pdr1 N-tag SacII and #Pdr1 N-tag BamHI and cloned into pYC46 as a SacII/BamHI fragment to generate pBC463 intermediate vector. Then, ∼500 bp of the N-terminal of PDR1, Pdr1 Down, was amplified with #Pdr1 N-tag XhoI and #Pdr1 Ntag KpnI and cloned into pBC463 as a XhoI/KpnI fragment to generate pBC464 (Supporting Information, Fig. S2A ). Then, we mutated the stop codon after the FLAG sequence with fusion PCR (Supporting Information, Fig. S2B ), generating N-terminal tagging cassette. This cassette was later transformed into the yeast cells ( Supporting Information, Fig. S2C ).
N-terminally 3 × HA-tagged triple ubiquitin driven by an inducible promoter was constructed as follows. An N-terminally 3 × HA-tagged triple ubiquitin was purchased as a synthetic sequence from Genewiz Biotechnology Company (Suzhou, China), the full sequence of which is listed in the supplemental data. Then, this synthetic sequence was fused with C. glabrata MT-II promoter at its N-terminal, as described previously (Costa et al. 2014) and expressed in URA3 locus in yeast cells.
Protein extraction, western blotting and quantitative real-time PCR
Protein extracts, western blotting and quantitative real-time PCR (RT-qPCR) were prepared as described previously (Thakur et al. 2008) . Briefly, cells were grown in YPD and harvested in log phase followed by preparation for protein extraction, western blotting and mRNA extraction. Anti-Flag M2 antibody (1:10 000 dilution, F3165, Sigma-Aldrich, USA), anti-HA antibody (1:1000 dilution; 05-902R; Millipore, USA) and anti-tubulin antibody (1:2000 dilution; YOL1/34; NOVUS, USA) were used to detect Pdr1, Gal11A and tubulin protein levels, respectively.
Coimmunoprecipitation assay
Coimmunoprecipitation (Co-IP) was performed in accordance with previously described immunoprecipitation protocols (Thakur et al. 2008) . The FLAG-tagged Pdr1 was immunoprecipitated by the addition of Anti-FLAG M2 Affinity Gel (catalog number A2220; Sigma) and eluted with 3 × FLAG peptide (catalog number F4799; Sigma). Immunoblotting was carried out as described in the section on western blotting.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) analysis was carried out in accordance with a standard protocol (Thakur et al. 2008) . Purified DNA was then analyzed by qPCR using LightCycler Roche 480 (Roche).
Immunofluorescence assay
The immunofluorescence assay was adapted from a previous immunofluorescence protocol (Wu and Huang 2008) . Anti-FLAG antibody (1:250 dilution in blocking buffer) was added to culture dishes followed by incubation for at least 2 h. PBS with 1% Tween-20 was then used to wash cells three times followed by the addition of anti-mouse antibody (1:1000 dilution; catalog number A32723; Thermo Fisher) at 25
• C in the dark for 1 h. After the cells had been washed three times with PBS, an antifade reagent with DAPI (catalog number P36935; Thermo Fisher) was added, and cells were examined and photographed with a Zeiss Axioplan2 microscope (Carl Zeiss, Jenna, Germany).
Drug susceptibility assays
Spotting assay was carried out as described previously (Borah et al. 2014) . Yeast cells were spotted on YPD plates with or without 16 or 64 μg/ml fluconazole in 10-fold serial dilutions.
The MIC values of fluconazole (Sigma, Shanghai, China), itraconazole (Sigma, Shanghai, China) and voriconazole (Sigma, Shanghai, China) of the clinical isolates were determined by the broth microdilution method, as described in the CLSI M27-A4 standard guidelines. Candida parapsilosis ATCC 20019 and C. albicans ATCC 90028 were used as control isolates. MIC breakpoints of voriconazole and fluconazole were determined in accordance with previous studies at 24 h (Pfaller et al. 2012) .
Subcellular fractionation
Subcellular fractionation assay was performed as described previously (Wu and Huang 2008) . Yeast cells from log-phase cultures were harvested and processed following the protocol (Wu and Huang 2008) . The cell lysates were spun at 13 000 rpm for 15 min. The supernatant was regarded as cytoplasm and the pellet as nuclei.
RESULTS
A unique GOF mutation was identified in a matched pair of C. glabrata clinical isolates
This project was originally initiated by searching for correlations between drug susceptibility and genomic mutations of CgPDR1 alleles from C. glabrata clinical isolates. Four matched pairs of C. glabrata clinical isolates were collected at Shanghai Ruijin Hospital in 2012. Each pair was collected from the same patient before and after azole treatment. A broth microdilution method was used to determine the minimum inhibitory concentrations for 80% (MIC 80 ) for a list of azole drugs including fluconazole, itraconazole and voriconazole (Table 1) . Among them, one strain (Wild6) exhibited the highest MIC 80 value for voriconazole and its matched pair (Wild5), as expected, conferred susceptibility to all selected azoles. Since mutations at the PDR1 transcriptional regulator locus were found to be associated with appearance of multiple drug resistance (Vermitsky et al. 2006; Ferrari et al. 2009 ), we sequenced the eight alleles of PDR1 present in these four matched pairs of clinical isolates. All SNP mutations are listed in Table 2 . Interestingly, a single amino acid substitution (GOF; G1037A) was identified in the PDR1 allele of strain Wild6 compared with that of Wild5. Because strain Wild6 has the highest MIC 80 value for voriconazole and other azole antifungals, as well as harbors only one GOF mutation at the PDR1 locus, we decided to choose it as a representative and carried out the remaining 
Mutants expressing N-or C-terminally 3 × FLAG-tagged Pdr1 confer strikingly different fluconazole susceptibility
In order to test whether a single amino acid difference of Pdr1 between Wild6 and Wild5 differs in drug susceptibility and has impact on its protein levels, we utilized epitope-tagged versions of Pdr1 in which three copies of the FLAG epitope were fused inframe at either the N-or C-terminus. To avoid potential difficulties in genetic manipulation of the clinical isolates, we deleted the URA3 gene in both Wild5 and Wild6 strains (the resulting strains were named TYS and TYR, respectively). Loss of URA3 had no effect on fluconazole susceptibility (Supporting Information, Fig. S3 ). Therefore, we were able to use URA3 as a selection marker and endogenously introduce a triple FLAG version of Pdr1 (N-or C-terminally) in each strain background by homologous recombination. As controls, the PDR1 gene was deleted in either TYS or TYR genetic background. All the strains used in this study were shown in Table S1 (Supporting Information). Figure 1a shows a schematic describing the constructs used in this approach. We first examine whether strains expressing epitope-tagged Pdr1 may display altered susceptibility to azole drugs. Overnight cultures of the indicated strains were diluted and spotted onto YPD plates supplemented with or without various concentrations of azole drugs such as fluconazole (Fig. 1b) , itraconazole, voriconazole and ketoconazole (Supporting Information, Fig.  S4 ). To our surprise, strains expressing the N-or C-terminally 3 × FLAG-tagged version of Pdr1 (R-Npdr1 or R-Cpdr1, respectively) displayed opposite fluconazole susceptibility, as we observed that expressing the C-terminally 3 × FLAG-tagged version of Pdr1 in an azole-resistant strain background caused a significant reduction in azole resistance whereas the Nterminally modified version showed even enhanced drug resistance (Fig. 1b) . As expected, deletion of PDR1 gene in either TYR or TYS caused an identical drug-susceptible pattern that the mutants exhibited to be hypersensitive to azole drugs, further supporting that genetically manipulating the highly regulated factor To ensure that the decreased fluconazole resistance in RCpdr1 was specifically due to the fusion with a triple FLAG epitope, we replaced the triple FLAG with a single FLAG. Immunoblotting analysis only detected a very weak expression of the single FLAG-tagged version of Pdr1, possibly because the antibody that we used was optimally designed for detection of a triple FLAG format. As shown in Fig. 1b , the resulting strain (R-1 × FLAG) restored the fluconazole resistance (fluconazole MIC 80 = 128 mg/L), a pattern consistent with a previous study that the strain expressing the C-terminally 1 × HA-tagged version of Pdr1 also confers a high level of azole resistance (Borah et al. 2014) . Thus, our results strongly suggest that the C-terminal sequence of Pdr1 appears to be vital for its regulatory activity and any types of modification in this region may have an impact on azole resistance.
The C-terminal modification on Pdr1 with 3 × FLAG leads to a reduction at mRNA and protein levels
Given that expression of a C-terminally 3 × FLAG-tagged form of Pdr1 results in abrogation of azole resistance, we investigated whether this is due to an effect of C-terminal modification on Pdr1 expression. To this end, we first assessed the protein level of Pdr1 in both R-Cpdr1 and S-Cpdr1 strain backgrounds by western blotting (Fig. 1c) . As expected, an extremely low level of Pdr1 was observed in S-Cpdr1. Interestingly, R-Cpdr1 also expressed a similarly low level of Pdr1, suggesting that tagging the C-terminus of Pdr1 with a triple FLAG significantly decreased its protein level. For comparison, high levels of Pdr1 were observed when it was N-terminally tagged with a trip FLAG, regardless of the strain background. In conclusion, our results indicate that modifying the C-terminal sequence of Pdr1 severely affects its protein level and, accordingly, influences C. glabrata resistance to azoles.
Next, we investigated whether the decreased protein levels in R-Cpdr1 may correlate with transcriptional downregulation of PDR1. RT-qPCR revealed that the mRNA level of PDR1 was decreased ∼50% when Pdr1 was C-terminally modified in both azole-resistant and sensitive strain backgrounds ( Fig. 1d and e) . As controls, there were ∼2-fold increases of PDR1 mRNA levels when it was N-terminally modified. Interestingly, the level of PDR1 mRNA also increased about 2 folds in the strain expressing a C-terminally 1 × FLAG-tagged version of Pdr1 (R-1 × FLAG), and this increase was consistent with an azole-resistant phenotype. Strain   Wild5  C162T, T226C, G271A,T293C, C309A, A427C, C705T, C765T, T871C, C1749T, A2319T, T2578C, T2994C, G3156A  Wild6 C162T, T226C, G271A, T293C, C309A, A427C, C705T, C765T, T871C, G1037A, C1749T, A2319T, T2578C, T2994C, G3156A Taken together, our data are in line with previous studies showing that N-terminal tagging on Pdr1 leads to a hyperactive form of Pdr1, similar to the role of GOF mutations (Vermitsky et al. 2006; Ferrari et al. 2009 Ferrari et al. , 2011a . However, unlike a single FLAG tag, tagging the C-terminus of Pdr1 with a triple FLAG significantly downregulated Pdr1 activity, suggestive of the presence of an as-yet-uncharacterized mechanism.
C-terminal modification of Pdr1 with a 3 × FLAG epitope alters its subcellular localization and downregulates the target genes
In S. cerevisiae, both Pdr1 and Pdr3 belong to the homolog of C. glabrata Pdr1 and are exclusively localized in the nucleus (Delahodde et al. 2001) ; we therefore hypothesized that the Cterminal modification promotes Pdr1 downregulation possibly through a change of subcellular localization. To test this hypothesis, we performed immunofluorescence analyses and unexpectedly observed that the C-terminally 3 × FLAG-tagged Pdr1 was localized exclusively in the cytoplasm (Fig. 1f) . In contrast, the N-terminally tagged Pdr1 was distributed in both cytoplasm and nucleus (Fig. 1f) . Considering that the transcription factor Pdr1 must be nuclear localized to regulate the expression of its target genes, it is very likely that a cytoplasmic mislocalization of the C-terminally 3 × FLAG-tagged version of Pdr1 may impair its regulatory function. Therefore, we test the expression levels of a number of classic drug-resistant genes, including CDR1, PUP1, CDR2, SNQ2
and PDR1 itself, all of those have been identified to be direct targets of Pdr1 (Vermitsky and Edlind 2004; Sanguinetti et al. 2005; Tsai et al. 2006 Tsai et al. , 2010 Torelli et al. 2008) . Meanwhile, CDR1 and PUP1 were found to be upregulated in all isolates harboring GOF mutations of Pdr1 (Ferrari et al. 2011) . A decreased expression level of PDR1 in the R-Cpdr1 strain prompted us to investigate whether the C-terminal modification of Pdr1 may affect expression of its target genes. Indeed, transcript levels of CDR1 and PUP1 were significantly decreased in R-Cpdr1 (Fig. 1d) and also in S-Cpdr1 (Fig. 1e) . For comparison, their expression levels were upregulated in both R-Npdr1 and S-Npdr1, and interestingly, the levels were even higher than those in the parent strains, suggesting the presence of additional regulation. Similar to the N-terminal modification, C-terminal modification of Pdr1 with a single FLAG led to upregulation of CDR1 and PUP1 (Fig. 1d) , consistent with the hyper-activation form of Pdr1 in this format.
The ubiquitin-proteasome proteolytic pathway only marginally contributes to decreased levels of the C-terminally 3 × FLAG-tagged Pdr1
Nuclear import and export of proteins are strictly controlled by the inner nuclear membrane which plays an important role in eliminating unfolded or misfolded proteins through the ubiquitin-proteasome pathway, and thus prevents nuclear accumulation and maintains normal cellular homeostasis (Foresti et al. 2014; Khmelinskii et al. 2014; Kaneko et al. 2016) . Our results have shown that the C-terminal modification of Pdr1 with a triple FLAG, but not a single FLAG, caused a dramatic decrease in its protein level (Fig. 1c) , a phenomenon that could not be fully explained by transcriptional downregulation, as we only observed a partial reduction in PDR1 transcript levels ( Fig. 1d  and e) . Therefore, it is reasonable to hypothesize that the Cterminally 3 × FLAG-tagged version of Pdr1 may be recognized as an unfolded or misfolded protein and undergo degradation via the ubiquitin-proteasome pathway. To test this hypothesis, we first examined the steady level of the C-terminally 3 × FLAGtagged version of Pdr1 after treatment with MG132, a potent proteasome inhibitor. We initially grew cells from strains R-Npdr1 and R-Cpdr1 in medium supplemented with MG132. However, problems were encountered in this experiment since the use of MG132 in these cells was hampered by the impermeability of the cell wall or membrane. Only an extremely high concentration of MG132 (up to 200 μM) was found to affect its protein levels (Supporting Information , Fig. S5) ; however, such a high dose might be toxic and affect cell viability. In the budding yeast S. cerevisiae, mutant strains (e.g. erg6 and pdr5 ) are required for experiments using the proteasome inhibitor MG132 since the mutant cells show increased drug permeability or reduced drug efflux (Lee and Goldberg 1996) . We therefore took the same approach by generating the ERG6-deficient mutants (erg6 ) in both R-Npdr1 and R-Cpdr1 backgrounds. Mutant cells were treated with or without the proteasome inhibitor MG132, using a concentration that was commonly used in S. cerevisiae (50 or 100 μM). As shown in Fig. 2a , MG132 treatment led to a partial but significant restoration of Pdr1 in the strain expressing a C-terminally 3 × FLAG-tagged version, although its level was still much lower than that expressing the N-terminally 3 × FLAGtagged Pdr1. As a control, the level of Pdr1 in the R-Npdr1 background was unaffected in the presence of MG132. Collectively, our results suggest that the decreased levels of the C-terminally 3 × FLAG modified Pdr1 may link to protein degradation via Figure 2 . The C-terminally 3 × FLAG-tagged version of Pdr1undergoes protein degradation via the ubiquitin-proteasome pathway. (a) Treatment with the proteasome inhibitor MG132 partially stabilized the C-terminally 3 × FLAG-tagged verison of Pdr1. Log-phase cells from R-Npdr1 or R-Cpdr1 were treated with or without MG132 at different doses. Protein extracts were subjected to Western analysis using antibodies against FLAG epitope and alpha-tubulin (loading control). (b) N-or C-terminally 3 × FLAG-tagged version of Pdr1 was polyubiquitinated. A 3 × HA-tagged form of ubiquitin was endogenously expressed under control of the copper-induced MT-II promoter in both R-Npdr1 and R-Cpdr1 strain backgrounds. Whole-cell extracts were prepared under non-denaturing conditions, and anti-FLAG M2 affinity gel was used to immunoprecipitate Nor C-terminally 3 × FLAG-tagged version of Pdr1. Pellets were subjected to immunoblot analysis using anti-HA antibodies to detect the presence of ubiquitin. a proteasome-dependent pathway. To further verify this, we test a possibility of ubiquitination since this modification represents a common signal for proteasome-mediated degradation (Hershko and Ciechanover 1998; Daraba et al. 2014) . In both RNpdr1 and R-Cpdr1 backgrounds, we created strains expressing an epitope-tagged 3 × HA-ubiquitin under the control of a copper-induced MT-II C. glabrata promoter. After a 5-h induction using CuSO 4 (30 μM), log-phase cells were collected and lysed, followed by immunoprecipitation of whole cell extracts with anti-FLAG antibodies. Protein ubiquitination was examined by immunoblotting with anti-HA antibody. In the strain expressing the C-terminally 3 × FLAG-tagged version of Pdr1, we expectedly observed a band pattern of the higher-molecular-mass forms, suggestive of the presence of polyubiquitinated forms of Pdr1 (Fig. 2b, lane 2) . Interestingly, the N-terminally tagged version of Pdr1 could also be polyubiquitinated, as a similar band pattern was detected (Fig. 2b, lane 1) . This is not a big surprise since a previous study has indicated that post-translational modifications such as ubiquitination are essential for transcription factors to avoid excessive gene expression and to facilitate interaction of transcription factors with the Mediator (Salghetti et al. 2001) .
Collectively, these results suggest that the transcription factor Pdr1, once expressed as a C-terminally 3 × FLAG-tagged version, could be polyubiquitinated and degraded by the ubiquitinproteasome pathway.
Proteasomal inhibition was unable to recover the defective regulatory function of the C-terminally 3 × FLAG-tagged Pdr1
A partial but significant restoration of the steady levels of the C-terminally 3 × FLAG-tagged Pdr1 after MG132 treatment prompted us to investigate whether this restoration may correlate with a functional recovery of Pdr1, including restoration of nuclear localization, azole resistance and expression of downstream targets.
First, we performed indirect immunofluorescence analyses to examine the subcellular localization of the C-terminally 3 × FLAG-tagged Pdr1 after MG132 treatment. As shown in Fig. 3a , MG132 treatment was unable to change the cytoplasmic localization of the C-terminally tagged Pdr1. The result was further confirmed by a subcellular fractionation assay using a protocol previously described in S. cerevisiae (Wu and Huang 2008) . Anti-histone H3 antibodies were used for assessment of the purity of the nuclear proteins and anti-α-tubulin antibodies were used as an internal control of the cytoplasmic fractions. Consistent with the results obtained from the immunofluorescence assays, we found that the C-terminally 3 × FLAG-tagged version of Pdr1 was still primarily restricted in the cytoplasm after MG132 treatment (Fig. 3b) . These data indicate that proteasomal inhibition, although partially restored the level of the C-terminally 3 × FLAG-tagged Pdr1, was unable to alter its cytoplasmic mislocalization.
Second, azole susceptibility assays were performed to assess the ability of proteasomal inhibition to recover drug resistance. Log-phase cells from strain R-Npdr1erg6 or R-Cpdr1erg6 were treated with or without MG132 for 2 h, serially diluted and spotted on YPD plates containing fluconazole, using a protocol described previously (Gujjula et al. 2016) . As shown in Fig. 3c , patterns of azole susceptibility of each strain were unaffected by MG132 treatment. Interestingly, we observed that loss of ERG6 increased cell susceptibility to azoles (Fig. 3c) , a phenotype that is in agreement with a previous study showing that a lack of the ERG6 gene not only improved cell wall permeability to inhibitors such as MG132 and cycloheximide but also promoted azole absorption (Vandeputte et al. 2007 ).
Finally, we examined the effect of MG132 treatment on transcript levels of the target genes of Pdr1. Log-phase cells from R-Cpdr1erg6 or R-Npdr1erg6 were treated with or without MG132 (50 μM) for 2 h and harvested for total RNA preparation. RT-qPCR analyses indicated that MG132 treatment had no effect on transcript levels of the drug-resistant genes such as CDR1, PUP1 and PDR1 (Fig. 3d and e) .
Taken together, our results suggest that proteasomal inhibition, although partially restored the protein level of the Cterminally 3 × FLAG-tagged Pdr1, was incapable of rescuing its defect in regulation of azole resistance. Therefore, it is more likely that protein degradation via the ubiquitin-proteasome pathway had only a minor effect on reduced protein levels of the C-terminally 3 × FLAG-tagged version of Pdr1, and other mechanisms, as yet uncharacterized, may majorly contribute to this regulatory defect.
The C-terminal modification of Pdr1 with a 3 × FLAG epitope disrupts its autoregulation in transcription
In S. cerevisiae, two zinc-finger transcription factors Pdr1 and Pdr3 act as master regulators of pleiotropic drug resistance (PDR) and their target gene promoters contain one or more typical binding sequences designated PDREs (PDR response elements) which correspond to a 8-bp consensus sequence (Wolfger et al. 1997; DeRisi et al. 2000) . Biochemical analyses have identified two putative PDRE sites in the C. glabrata Pdr1 promoter, at positions −701 to −693 (PDRE1) and positions −557 to −549 (PDRE2), respectively (Paul, Bair and Moye-Rowley 2014) , and studies have shown that expression of PDR1 gene is transcriptionally autoregulated, possibly through its binding to the PDREs. When we removed the single or both PDRE sequences from the PDR1 gene promoter in a TYR background, we found in Fig. 4a that both regions are required for the full resistance to fluconazole, as deleting any one of the two PDREs dramatically decreased fluconazole resistance. Moreover, PDRE2 appears to have a greater impact on fluconazole resistance because deleting this element exhibited a stronger defect in fluconazole resistance when compared to the effect of PDRE1 deletion. Accordingly, we observed that each of PDRE deletion significantly decreased transcript levels of PDR1, and obviously, deletion of both PDREs caused a more dramatic impact leading to a ∼70% loss of PDR1 expression (Fig. 4b) . Moreover, we observed that the classic Pdr1 target genes such as CDR1 and PUP1were transcriptionally downregulated in mutants lacking the PDREs (Fig. 4b) . These results highly suggest that as in S. cerevisiae, the PDREs present in the PDR1promoter in C. glabrata also play essential roles in its transcriptional autoregulation.
Similar to the effect of PDRE deletion, a C-terminal modification of Pdr1 with a triple FLAG in the TYR strain background also significantly decreased the expression of PDR1 and diminished azole resistance. We therefore hypothesized that the Cterminally modified Pdr1 may fail to bind to the PDRE sequence and therefore dampened transcriptional autoregulation. To test this hypothesis, we performed ChIP assays in strains expressing different versions of 3 × FLAG-tagged Pdr1. Logarithmically growing cells from R-Npdr1 and R-Cpdr1 strains were harvested, whole-cell extracts were incubated with monoclonal antibodies against the FLAG epitope and immunoprecipitated DNA was collected. Using primer sets flanking the putative PDREs of the PDR1gene promoter, we performed qPCR analyses and observed that Pdr1is highly enriched at the two PDREs in strain R-Npdr1 whereas its binding was dramatically diminished (∼54% loss) in strain R-Cpdr1 (Fig. 4c) , suggesting that the C-terminal modification decreased the binding of Pdr1 to its own promoter and therefore attenuated the transcriptional autoregulation. Using the same approaches, we also profiled the binding of Pdr1 to the PDREs ofCDR1 and PUP1 gene promoters in strains R-Npdr1 and R-Cpdr1. Similar results were obtained, as we found that the amount of Pdr1 bound to CDR1 and PUP1 in R-Cpdr1 was reduced to ∼ 1.7% and 36% of that in R-Npdr1, respectively ( Fig. 4d and  e) . Taken together, these results demonstrate that C-terminal modification attenuates autoregulation of Pdr1, defining a pivotal role of the C-terminal sequence in regulating its transcription.
C-terminal modification of Pdr1 with a 3 × FLAG epitope has no effect on the regulatory role of 3 UTR Given the importance of the 3 untranslated regions (UTRs) in the regulation of gene expression (Barrett, Fletcher and Wilton Figure 3 . Proteasomal inhibition is insufficient to recover Pdr1 regulatory activity once it is C-terminally tagged with a triple FLAG. (a) Indirect immunofluorescence of N-or C-terminally 3 × FLAG-tagged version of Pdr1 in an erg6 null background. Cells were treated with or without the proteasome inhibitor MG132. DIC represents phase images, FITC represents N-or C-terminally 3 × FLAG-tagged Pdr1 staining, DAPI represents DNA staining, and merge represents the overlap of FLAG-tagged Pdr1 and DNA staining. Scale bar, 10 μm; all images were obtained at the same magnification. (b) Subcellular fractionation. As in A, the same strains and treatments were employed. The nuclear and cytoplasmic fractions of indicated strains were prepared following a previously described protocol (details can be available in 'Materials and Methods' section) and resolved by SDS-PAGE. The separated proteins were transferred to nitrocellulose membranes and Western analysis was performed using anti-FLAG to detect Pdr1. To ensure the purity of cytoplasmic or nuclear fraction, anti-tubulin (a cytoplasmic marker) and anti-histone H3 (a nuclear marker) antibodies were used. (c) Fluconazole susceptibility profiling. Cells from indicated strains were pretreated with or without MG132 for 2 h at indicated doses and then spotted in serial dilutions onto YPD medium supplemented with different concentrations of fluconazole. Plates were incubated at 30
• C for 48 h. (d, e) RT-qPCR analysis of CDR1, PUP1 and PDR1 expression in the same strains. Cells were treated as described in A. The values were normalized by ACT1 expression. All values were the average of three independent experiments, with error bars representing the SEM.
2012), we next ask whether the C-terminal modification of Pdr1 disrupts its transcriptional autoregulation possibly by interfering with regulatory activity of the 3 UTR. To test this possibility, we removed the 3 UTR of the PDR1 gene in the TYR strain background and test the azole susceptibility. Interestingly, the lack of 3 UTR did not alter the azole sensitivity (Fig. 5a ), suggesting that inhibition of Pdr1 transcriptional autoregulation in strain RCpdr1 could not be explained by a potential dysfunction of the 3 UTR.
C-terminal modification of Pdr1 with a 3 × FLAG epitope disrupts its interaction with the mediator complex subunit Gal11A
It has been well documented that Pdr1 executes its regulatory function by allowing the C-terminal activation domain to interact with Gal11A, a subunit of the mediator co-activator, and thus facilitating recruitment of RNA polymerase II (Pol II) 2016). To test whether transcriptional autoregulation of Pdr1 may require Gal11A, we individually deleted the GAL11A gene in azole-resistant (TYR and R-Npdr1) and azole-sensitive (R-Cpdr1) strain backgrounds. As shown in Fig. 5a , deletion of GAL11A in azole-resistant strain backgrounds resulted in decreased fluconazole resistance, supporting the notion that an interaction between Pdr1 and Gal11A is required for activation of drugresistant genes like CDR1 (Thakur et al. 2008; Nishikawa et al. 2016) . Consistent with these phenotypes, transcript levels of PDR1, CDR1 and PUP1were dramatically decreased when GAL11A was deleted from either TYR or R-Npdr1 strain ( Fig. 5b and c) .
In comparison, we observed that loss of GAL11A in strain RCpdr1 had no effect on the fluconazole susceptibility ( Fig. 5a ) and caused only an ∼ 10% reduction in transcript levels of PDR1 and CDR1 (Fig. 5d) . Interestingly, protein levels of Pdr1 were severely affected by GAL11A deletion in R-Npdr1 but not R-Cpdr1 (Fig. 5e) . These results were strongly consistent with previous studies (Thakur et al. 2008; Tumbarello et al. 2008; Nishikawa et al. 2016) and suggested that the C-terminus of Pdr1 was actively involved in regulating azole resistance through its interaction with Gal11A. To confirm this, we deleted the last 90-bp C-terminal sequences of PDR1, a region that has been verified to directly interact with Gal11A (Thakur et al. 2008 , Nishikawa et al. 2016 . We found that deletion of the last 90-bp C-terminal sequence of PDR1 abrogated the azole resistance (Fig. 5a ) and abolished expression of drug resistance genes such as PDR1, CDR1 and PUP1 (Fig. 5f ), strongly suggesting that Pdr1 interacts with Gal11A through its C-terminus and this interaction contributes to azole resistance. Since we used two different genetic methods, including deletion of the last 90-bp binding sequence and direct fusion of a triple FLAG to the carboxyl terminus, to evaluate the impact of PDR1 terminus on azole resistance and obtained almost identical phenotypes, it is very likely that the C-terminal modification of Pdr1 with a triple FLAG may interfere with the interaction with Gal11A and thus adversely affected transcriptional autoregulation of Pdr1 and phenotypes of azole resistance. To test this possibility, we individually expressed the Cterminally 3 × HA-tagged Gall1A in strain R-Npdr1 or R-Cpdr1 and examined interactions between Gal11A and the N-or Cterminally modified Pdr1. Expression of an epitope-tagged version of Gal11A showed no changes in Pdr1 target gene expression and azole resistance ( Supporting Information, Fig. S6 ). Co-IP experiments using anti-FLAG antibodies to explore Pdr1-Gal11A interactions in cell lysates from strains expressing N-or Cterminally 3 × FLAG tagged Pdr1 were shown in Fig. 6a . Both N-and C-terminally 3 × FLAG-tagged Pdr1 could be efficiently co-immunoprecipitated with Gal11A-3 × HA (lanes 1 and 2), suggesting that the N-or C-terminal modification of Pdr1 with a triple FLAG did not interfere with its interaction with Gal11A, however, the interactions correlate with opposite effects. To gain insight into the effect of Gal11A interaction on Pdr1 function, we monitored co-localization of Gal11A with N-or C-terminally tagged version of Pdr1 by indirect immunofluorescence assays (Fig. 6b) . We observed that Pdr1 was aberrantly mislocalized to the cytoplasm once it is C-terminally 3 × FLAG-tagged whereas the N-terminally modified version was regularly nuclear localized (Fig. 6b) . Strikingly, the C-terminally 3 × FLAG-tagged version of Pdr1 was co-localized with Gal11A primarily in the cytoplasm whereas the co-localization occurred in both cytoplasm and nucleus in the strain expressing a N-terminally 3 × FLAGtagged version of Pdr1, supporting the proposition that the interactions between Gal11A and the N-or C-terminally 3 × FLAGtagged Pdr1 may occur in different subcellular compartments. On the other hand, because Gal11A, by interacting with the Cterminus of Pdr1, facilitates the recruitment of RNA polymerase II (Pol II) to the target gene promoters and this can only happen in the nucleus (Thakur et al. 2008; Nishikawa et al. 2016) , we speculated that the cytoplasmic interaction between the Cterminally modified Pdr1 and Gal11A, although it seems to be more evident, may be non-functional. In other words, Gal11A may fail to be recruited to the promoters of drug-resistant genes such as PDR1, CDR1 and PUP1. To test this, we created strains co-expressing a 3 × HA-tagged version of Gal11A and a Nor C-terminally 3 × FLAG-tagged Pdr1 (R-Npdr1gal11 and RCpdr1gal11, respectively), and carried out ChIP experiments using anti-HA antibodies. The whole cell extracts derived from logarithmically growing cells were incubated with monoclonal antibodies against the HA epitope, and immunoprecipitated DNAs were collected for qPCR analyses. Apparently, Gal11A was highly enriched at the PDREs located at the promoters of selected genes in the strain expressing the N-terminally 3 × FLAG-tagged version of Pdr1 whereas the enrichment was dramatically diminished in the strain expressing a version of Cterminally modified Pdr1 (Fig. 6c) . Taken together, our data indicate that the C-terminal modification of Pdr1 with a triple FLAG epitope did not interfere with its interaction with Gal11A; however, this interaction mainly occurs Figure 6 . C-terminal modification of Pdr1 with a triple FLAG results in an irregular interaction with Gal11A. (a) Co-IP between Gal11A-HA and N-or C-terminally 3 × FLAG-tagged version of Pdr1. A C-terminally 3 × HA-tagged Gal11A was individually expressed in the TYR, R-Npdr1 or R-Cpdr1 strain background. Cells were grown in YPD medium to a middle log phase. Whole-cell extracts were prepared under non-denaturing conditions, and anti-FLAG M2 affinity gel was used to immunoprecipitate 3 × FLAG-tagged Pdr1 and associated proteins. Immunoprecipitates were subjected to Western analysis, using antibodies against the HA epitope to identify Gal11A-3 × HA. (b) Indirect immunofluorescence assay to detect a possible colocalization of Gal11A-3 × HA with N-or C-terminally 3 × FLAG-tagged version of Pdr1. Shown for cells cultured in YPD medium. Scale bar, 10 μm; all images were obtained at the same magnification. (c) ChIP was performed with HA antibodies in R-Npdr1gal11 and R-Cpdr1gal11 strains, each co-expressing the N-or C-terminally 3 × FLAG-tagged version of Pdr1 with a 3 × HA-tagged version of Gal11A, respectively. HA-ChIP DNA was subjected to qPCR to validate Pdr1 binding to the PDRE promoter regions of indicated genes. The untagged parental strain TYR was used for a ChIP control. ' * * ' represents P ≤ 0.01. Values are the mean ± SD from three independent experiments.
in the cytoplasm and therefore fails to activate the transcriptional autoregulation of Pdr1. Phenotypically, the strain displays decreased resistance to azole drugs.
DISCUSSION
Candida glabrata is the second most common Candida species that causes invasive fungal infection. Because of its innately low susceptibility to azoles and rapid development of azole drug resistance following exposure, C. glabrata has become an important difficult-to-treat cause of infection (Vermitsky and Edlind 2004; Ruan et al. 2008; Pfaller et al. 2012; Vale-Silva and Sanglard 2015; Nabili et al. 2016) . Notably, more than 95% of azole-resistant C. glabrata isolates were found to harbor GOF mutations in their PDR1 alleles (Ferrari et al. 2009 ), highlighting the critical role of Pdr1 in azole resistance. In this study, we unexpectedly found that the C-terminally 3 × FLAG-tagged version of Pdr1, when expressed in an azole-resistant clinical isolate harboring a single GOF mutation, resulted in decreased PDR1 and CDR1 expression, as well as abrogation of azole resistance. Our data support the proposition that decreased mRNA and protein expression of the C-terminally tagged Pdr1 were predominantly due to impaired transcriptional autoregulation, which includes insufficient binding to its own promoter and non-functional cytoplasmic interaction with the Mediator subunit Gal11A. Moreover, protein turnover via the ubiquitin-proteasome pathway also contributes to the decreased level of C-terminally modified Pdr1. To the best of our knowledge, our results provide the first description of the mechanism by which C-terminal modification downregulates Pdr1 expression by targeting its transcriptional autoregulation.
Contrary to the effect of a triple FLAG epitope, we observed that C-terminally tagged Pdr1 with a single FLAG yielded a hyperactive phenotype, as indicated by increased azole resistance and transcriptional upregulation of Pdr1 target genes. This is consistent with a recent study showing that a C-terminalmodified version of Pdr1 with a single HA epitope was hyperactive (Borah et al. 2014) . Moreover, previous studies have shown that both N-and C-terminal tagging result in a hyperactive form of Pdr1 (Borah et al. 2014) . Interestingly, our results showing that C-terminally 3 × FLAG-tagged Pdr1 dampened azole resistance seem to challenge this idea, although we did find that Nterminal tagging with a triple FLAG generated a hyperactive form of Pdr1, possibly because the N-terminal DNA-binding domain of this version of Pdr1 may exhibit higher affinity for promoters of its downstream targets in a way similar to that associated with the GOF mutations.
In C. glabrata, Pdr1 regulates its own expression mainly through a transcriptional autoregulation pathway, which requires two steps: first, Pdr1 protein uses its N-terminal DNAbinding domain to bind to the PDRE sequence present in its promoter (Delahodde, Delaveau and Jacq 1995; Paul, Schmidt and Moye-Rowley 2011) ; second, Pdr1 interacts with the mediator subunit Gal11A through its C-terminal activation domain and facilitates the recruitment of RNA PolII (Thakur et al. 2008; Nishikawa et al. 2016) . The evidence provided in this study strongly supports the conclusion that expression of the C-terminally 3 × FLAG-tagged version of Pdr1 reverses the azole resistance by disrupting its transcriptional autoregulation. First, our data confirmed that the two major steps of Pdr1 transcriptional autoregulation, including the binding of Pdr1 to the PDREs and interaction with Gal11A, both appear to be important for regulating the expression level of PDR1. We found that removal of the PDRE sequence or deletion of GAL11A both resulted in dramatic reduction of PDR1 expression (Figs 4b and 5b) , whereas the 3 -UTR seems to be dispensable for azole resistance (Fig. 5a) , highlighting the critical role of this transcriptional autoregulation pathway in PDR1 expression and azole resistance. Second, the C-terminal modification with a triple FLAG severely affected the mRNA and protein expression of Pdr1 by targeting both steps of Pdr1 autoregulation. ChIP analyses (Fig. 4c) clearly showed that C-terminal tagging significantly reduced the binding of Pdr1 to its promoter, possibly due to the decreased level of Pdr1 protein. Surprisingly, we unexpectedly observed that the C-terminally modified Pdr1 was still able to interact with Gal11A in a similar way as its N-terminal modification (Fig. 6a) ; however, this interaction turned out to be inefficient since it failed to promote the expression of Pdr1, which could be explained by the irregular cytoplasmic localization of the two proteins (Fig. 6b) . Taken together, these results demonstrate for the first time that a C-terminal modification of Pdr1 negatively affects C. glabrata azole resistance by attenuating its transcriptional autoregulation.
Given the importance of the unfolded protein response (UPR) in protein degradation, we speculate that a C-terminal modification of Pdr1 with a triple FLAG epitope may somehow alter the protein structure and then the resulting unfolded or misfolded protein, once expressed, may trigger the UPR, which has been shown to play a critical role in controlling protein import into the nucleus and export from it (Lee and Goldberg 1996; Boban and Foisner 2016) . Indeed, we observed irregular cytoplasmic localization of the C-terminally 3 × FLAG-tagged version of Pdr1, which caused a non-functional interaction with Gal11A ( Fig. 6a  and b) , since the process of transcriptional autoregulation requires a nuclear interaction between Pdr1 and GalllA (Thakur et al. 2008; Nishikawa et al. 2016) . Moreover, the inner nuclear membrane plays an important role in eliminating unfolded or misfolded proteins through the ubiquitin-proteasome pathway to prevent their nuclear accumulation and maintain normal cellular homeostasis (Lee and Goldberg 1996; Boban and Foisner 2016) . Consistent with this, excessive degradation of Pdr1 was observed in the azole-resistant clinical isolate expressing the Cterminally 3 × FLAG-tagged version of Pdr1 and notably, degradation of this C-terminally tagged version of Pdr1 appeared to occur through the ubiquitin-proteasome pathway ( Fig. 2a and b) . However, our data ruled out the possibility that this ubiquitinmediated proteolytic pathway mainly contributes to dampened autoregulation in transcription, as proteosomal inhibition was unable to restore the expression and subcellular localization of Pdr1, even we did observe that supplementation of the proteasomal inhibitor MG132 increases the protein level of Pdr1. These data highly suggest that C-terminal modification of Pdr1 alters the function of this master regulator in azole resistance.
A surprising finding was that, although the R-Cpdr1 strain exhibited attenuated azole resistance (Fig. 3c) , loss of ERG6 in this strain background led to the overexpression of CDR1 (Fig. 3d) , the expression of which normally accounts for increased azole resistance of C. glabrata clinical isolates (Sanguinetti et al. 2005; Tsai et al. 2006 Tsai et al. , 2010 . Actually, this is not a single case, as a previous study also showed that CDR1 was overexpressed about 27-fold in an azole-susceptible C. glabrata clinical isolate harboring a single silent mutation in the ERG6 allele (Vandeputte et al. 2007) . Taking into account the involvement of the ABC transporters such as Cdr1 in changes in plasma membrane permeability in C. albicans and S. cerevisiae (Kohli et al. 2002; Pasrija, Panwar and Prasad 2008) , it is reasonable to assume that a lack of ERG6 in C. glabrata destroys the production of ergosterol and inhibits Cdr1 actions on the cellular membrane. As stated previously, Pdr1 controls the expression of genes required for sphingolipid and phospholipid synthesis (Shingu-Vazquez and Traven 2011) , and changes in membrane structure/composition may activate multidrug resistance pathways to compensate for the loss of ergosterol in the cell membrane. Thus, the loss of ERG6 may lead to the accumulation of sterol intermediates that require Cdr1 to be eliminated.
The mechanism underlying the interaction of Pdr1 with the coactivator Gal11A through its C-terminal activation domain remains poorly understood. In S. cerevisiae, the activation domain alone is sufficient for Pdr1 to interact with the Mediator and other factors involved in its transcriptional machinery (Thakur et al. 2008; Nishikawa et al. 2016) . Interestingly, the Pdr1 activation domain was found to be exchangeable with the one present in Gal4, a master transcriptional regulator responsible for galactose-mediated gene induction in S. cerevisiae (Devaux et al. 2001; Thakur et al. 2008) , suggesting that they may share mechanisms of gene regulation. The activation domain of Gal4 facilitates the recruitment of coactivators and other transcriptional regulators to promoters of its target genes, thereby activating gene transcription (Wu, Reece and Ptashne 1996; Chang et al. 2001 ), a mode of action that is exactly the same as that
